Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|June 4, 2020
Cryogenic Capsule for Shipment of Cellular Therapies
Author(s)Pharmaceutical Technology Editors
The VIA Capsule from Cytiva is a liquid nitrogen-free cryogenic shipment system designed to transport cell therapies.
The VIA Capsule from Cytiva is a liquid nitrogen-free cryogenic shipment system for the shipment of cellular therapies and cryopreserved apheresis to ensure cell viability during the logistics process from the manufacturer to patient.
The system features a Stirling cryocooler, which cools the shipper unit prior to transportation and provides temporary cryogenic storage when connected to a power source. The internal thermal core provides five days of passive standby when disconnected from a power source; an LCD interface shows the temperature of the shipment and time remaining at cryogenic temperature, Cytiva reports.
A smart monitor uploads temperature, condition, and location information to a dashboard in the Chronicle software platform. The system is equipped with wheels for transport in a hospital setting.
In the event of transportation delays, VIA Capsule shippers can be held on-charge at a Cytiva-certified VIA Capsule Charge Station through World Courier until transportation can resume.
Demonstration units will be available in August 2020 for customers in Europe and the United States for validation testing, the company reports.
Cytiva is formerly part of GE Healthcare Life Sciences
Source:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.